Who owns XLO?
Institutional ownership of Xilio Therapeutics Inc. from Form 13F, Q2 2026
25 institutional managers reported holding Xilio Therapeutics Inc. (XLO) in Form 13F filings for Q2 2026, with 2,756,592 shares worth $26.4M. The largest reported holder was Bain Capital Life Sciences Investors, LLC. Managers that filed both quarters added a net 791,706 shares (+40.3%). 10 opened new positions and 7 sold out.
- Funds holding
- 25
- Value held
- $26.4M
- New / sold out
- 10 / 7
- Net shares, same filers
- +40.3%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of XLO
Share of 13F holdings is each fund's shares as a share of the 2,756,592 XLO shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Orbimed Advisors LLC New+$5.7M
- Stonepine Capital Management, LLC Added+$1.6M
- Adage Capital Partners GP, L.l.c. New+$1.1M
- Vanguard Capital Management LLC Added+$526K
- Citadel Advisors LLC New+$249K
- Bridgeway Capital Management, LLC New+$168K
- Renaissance Technologies LLC Added+$140K
- Two Sigma Investments, LP New+$139K
- Prelude Capital Management, LLC New+$111K
- BlackRock, Inc. New+$84K
Biggest sellers in Q2 2026
- Caligan Partners LP Sold out-$943K
- AJU IB Investment Co., Ltd. Sold out-$401K
- FMR LLC Sold out-$307K
- Ghisallo Capital Management LLC Sold out-$116K
- Vanguard Fiduciary Trust Co Trimmed-$56K
- UBS Group AG Trimmed-$39K
- Gsa Capital Partners LLP Trimmed-$32K
- Morgan Stanley Trimmed-$5K
- JPMorgan Chase & Co Sold out-$2K
- Vanguard Global Advisers, LLC Sold out-$2K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $9.7M and sold $1.9M; 4 added and 4 trimmed.
Schedule 13D and 13G filings on XLO
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-17ADAR1 Capital Management, LLC SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
- 2026-11-12Adage Capital Management, L.P. SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
- 2026-05-15ORBIMED ADVISORS LLC SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
- 2025-12-11Coastlands Capital LP SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
- 2025-06-17Point72 Asset Management, L.P. SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
- 2025-02-18AbbVie Inc. SCHEDULE 13G filed by Xilio Therapeutics Inc.Schedule 13G
Questions about XLO ownership
- Who owns XLO stock?
- 25 institutional investment managers reported XLO positions in their Form 13F filings for Q2 2026, holding 2,756,592 shares worth $26.4M in total. Bain Capital Life Sciences Investors, LLC reported the largest position.
- Are funds buying or selling XLO?
- In Q2 2026, 10 managers opened new XLO positions, 4 added, 4 trimmed and 7 sold out. Managers that filed in both quarters added a net 791,706 shares.
- How current is this XLO institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to XLO by CUSIP. Options are left out. XLO news and filings · XLO insider trades · Top funds